Vol. 7, Issue 1, Part B (2025)

Betulinic acid, a naturally occurring pentacyclic triterpenoid, has garnered considerable attention for its diverse pharmacological properties, including anti-inflammatory, anticancer, and neuroprotective effects. This study aims to evaluate the anti-Alzheimer potential of Betulinic acid. Alzheimer's disease (AD), characterized by cognitive decline and neurodegeneration, is associated with the accumulation of amyloid- beta plaques and neurofibrillary tangles. In this investigation, Betulinic acid was then tested for its ability to inhibit acetylcholinesterase (Ach-E), an enzyme that breaks down acetylcholine and whose inhibition is a common therapeutic strategy for AD. In vitro studies demonstrated significant Ach-E inhibitory activity of Betulinic acid, comparable to standard anti-Alzheimer drugs. Furthermore, in vivo studies on transgenic mouse models of AD showed that Betulinic acid administration improved cognitive functions and reduced amyloid plaque burden in the brain. These findings suggest that Betulinic acid from exhibits promising anti-Alzheimer effects, potentially through Ach-E inhibition and amyloid plaque reduction. Thus, Betulinic acid may serve as a valuable lead compound in the development of novel therapeutic agents for Alzheimer's disease.